tbuckley/cabot-search huggingface dataset:
Phase II clinical trial with a second generation, GM-CSF encoding, oncolytic herpesvirus in unresectable metastatic melanoma
Authors: N. N. Senzer, H. L. Kaufman, T. Amatruda, M. Nemunaitis, T. R. Reid, C. Love, T. Marshall, H. Goldsweig, R. S. Coffin, J. J. Nemunaitis
Journal: Journal of Clinical Oncology (2008)

9008 Background: OncoVEXGM-CSF is a 2nd generation oncolytic HSV, encoding GM-CSF, which was previously well tolerated in a phase I trial where both injected and uninjected anti-tumor effects were seen. Methods: Inclusions: Unresectable stage IIIc/IV melanoma with ≥1 injectable tumor (ultrasound allowed), failed prior therapy. Exclusions: Clinically active brain, liver, or bone metastases. ≤10 lesions are injected. ≥1 lesion must be left uninjected. Dosing schedule: 1 injection of ≤4ml of 106 pfu/ml split between target tumors, followed 3 wks later by ≤24 injections of 108 pfu/ml every 2 wks. Study design: Single arm monotherapy in up to 50 evaluable pts. ≥1 RECIST response amongst the first 24 pts required to continue. End points: Response rate (RECIST; primary), safety, response kinetics, survival. Results: The study has enrolled 40 pts, 31 evaluable (≥4 injection cycles or early clinically relevant PD; 19% stage IIIc, 32% IVM1a, 3% M1b, 45% M1c). Pts have had up to 18 injection cycles. Injected tumors have routinely responded by 2 mo on therapy, often with local CR and frequently providing palliative benefit. With respect to systemic responses, 3 pts have CR, 3 PR, 4 durable SD, & 2 MR (mixed response; ≥PR of existing disease and ≥PR of lesions which became measurable later). 2 further pts have had post treatment objective responses. Systemic responses are in both stage IIIc and IV pts, including resolution of visceral disease, and are delayed with respect to injected tumor responses taking up to 10 mo to fully develop. All objective responses have been maintained to date at 4 to 23 mo post first dose, with those not CR still on therapy. Side effects have been grade 1 flu-like symptoms, as in phase I. Conclusions: Per protocol treatment success (CR, PR or durable SD) has been seen in 32% of pts. Other pts have also had clinical benefit, including 2 pts where tumors first noted during therapy responded, 2 pts who responded after leaving the study for PD, and other pts with local palliative benefit in otherwise difficult to treat tumors. The rate and durability of response is impressive compared to other treatment options available to patients with advanced melanoma, particularly in the second line/salvage therapy setting. Further evaluation is therefore warranted. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration BioVex Inc BioVex Inc BioVex Inc
THE UTILITY OF ANTIPLAGUE VACCINES
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Response: Re: Intensity-Modulated Radiation Therapy Dose Prescription, Recording, and Delivery: Patterns of Variability Among Institutions and Treatment Planning Systems
Authors: I. J. Das, C. W. Cheng, K. L. Chopra, R. K. Mitra, S. P. Srivastava, E. Glatstein
Journal: JNCI Journal of the National Cancer Institute (2008)
WW II
Authors: Lester S. King
Journal: JAMA (1975)

How futile to compare the relative worth of pictures and of words! Each category may be expressed in its own way. But when we combine expressive pictures with a gem-like text, the effect is profound. Such a combination we have in<i>WW II</i>, which I deem one of the great war books of all time. The core of the handsomely published volume is a selection of pictures—not photographs but paintings and drawings (with a few cartoons)— dealing with World War II, created by men who were<i>there</i>, a lived-through experience that they put on paper or canvas. Large paintings of battle scenes, small sketches of more personal or intimate events, the pictures range widely in subject matter and technique, but all have impact. The text by James Jones (author of<i>From Here to Eternity</i>) is a series of vignettes that in the aggregate cover the entire war, in approximate chronological
Commentaire du travail de Haapamäki C et al., pp. 605
Journal: Endoscopy (2015)

See also: Randomized multicenter study of multiple plastic stents vs. covered self-expandable metallic stent in the treatment of biliary stricture in chronic pancreatitisEndoscopy 2015; 47(07): 605-610DOI: 10.1055/s-0034-1391331
AN ANALYSIS OF GASTRO-ENTEROSTOMY AND ITS FAILURES
Journal: JAMA (1921)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Erratum
Journal: JNCI Journal of the National Cancer Institute (1994)

“Prospective Study of Plasma Fatty Acids and Risk of Prostate Cancer,” by P. H. Gann, C. H. Hennekens, F. M. Sacks, et al. [J Natl Cancer Inst 86:281–286, 1994 (Issue 4)]. The authors wish to correct an error: “The ‘Patients and Methods’ section (p. 282) states that plasma fatty acid composition was measured in the cholesterol ester lipid fraction. However, the data in the report refer to fatty acids in the phospholipid fraction. The relative amount of individual fatty acids does vary according to the lipid fraction in which they are measured. However, fatty acid levels in both cholesterol ester and phospholipid fractions are responsive to general dietary patterns, and it is not clear which fraction might be more relevant in the etiology of prostate cancer. Plasma phospholipids are thought to be involved in a dynamic equilibrium with phospholipids in erythrocyte, and possibly other, cell membranes. We are currently completing an analysis of fatty acid composition in the cholesterol ester fraction of the same plasma samples.”
JAMA Dermatology
Journal: JAMA Dermatology (2013)

Mission Statement JAMA Dermatology publishes information concerning the skin, its diseases, and their treatment.Its mission is to explicate the structure and function of the skin and its diseases and the art of using this information to deliver optimal medical and surgical care to the patient.We attempt to enhance the understanding of cutaneous pathophysiology and improve the clinician's ability to diagnose and treat skin disorders.This journal has a particular interest in publishing clinical and laboratory studies that reveal new information pertinent to the interests and needs of the medical dermatologist, dermatologic surgeon, and all those concerned with state-of-the-art care of cutaneous disease.We believe that knowledge derived from well-designed clinical trials and studies of cost-effectiveness are especially important for improving the practice of dermatology.Studies that increase the understanding of the outcome of treatment or the means by which the burden of dermatologic disease can be measured and reduced to promote the health of patients with skin disease will receive special priority.The journal regularly publishes reports on clinical investigations, editorials, and reviews.It also features reports and discussions on clinicopathologic correlations; clinical disorders of unique didactic value; pharmacologic, medical and surgical therapeutics; and ethical, moral, socioeconomic, and political issues.
Transactions of the Michigan State Medical Society for the year 1897.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hepatitis C virus core protein activates ERK and p38 MAPK in cooperation with ethanol in transgenic mice
Authors: Takeya Tsutsumi, Tetsuro Suzuki, Kyoji Moriya, Yoshizumi Shintani, Hajime Fujie, Hideyuki Miyoshi, Yoshiharu Matsuura, Kazuhiko Koike, Tatsuo Miyamura
Journal: Hepatology (2003)

In human chronic hepatitis C, alcohol intake is a synergistic factor for the acceleration of hepatocarcinogenesis. Recently, we showed a significant increase of reactive oxygen species (ROS) in hepatitis C virus (HCV) core-transgenic mice fed ethanol-containing diets. Because previous studies indicated that ROS is closely associated with mitogen-activated protein kinases (MAPK), we examined activities of c-Jun N-terminal kinase, p38 MAPK, and extracellular signal-regulated kinase (ERK) in the liver of core-transgenic and nontransgenic mice with short-term ethanol feeding. Activity of ERK and p38 MAPK was increased in core-transgenic mice compared with nontransgenic mice, whereas neither ERK nor p38 MAPK was activated in core-transgenic mice with normal diets. In addition, activity of cyclic-AMP and serum responsive element, downstream pathways of p38 MAPK and ERK, was also increased. Comparison of gene expression profiles by cDNA microarray and real-time PCR revealed that galectin-1, which is associated with cell transformation, was significantly increased in ethanol-fed core-transgenic mice. On the other hand, glutathione S-transferase (GST), which plays a key role in protecting cells from oxidative stress, was decreased. In conclusion, these results suggest that HCV core protein cooperates with ethanol for the activation of some MAPK pathways, and leads to the modulation of several genes, contributing to the pathogenesis of liver disease of HCV-infected patients with high ethanol consumption.
Pathogenesis and Treatment of Hepatic Failure
Authors: Thomas C. Chalmers
Journal: New England Journal of Medicine (1960)

IN a review of hepatic coma published in this journal eleven years ago1 the statement was made that, "in spite of a long-continued search for a metabolic toxin in liver coma, none has been demonstrated." Within a few years a continuing flood of papers on the biochemical and clinical effects of ammonia in hepatic coma was started by the observations that impending coma could be produced by ammonia-releasing substances such as cation-exchange resins, urea and dietary protein.2 3 4 5 It was fitting that this rediscovery of ammonia toxicity in liver disease was made at the same time in France,6 for it was . . .
Effect of nicotine chewing gum as an adjunct to general practitioners' advice against smoking
Authors: M A H Russell, J Stapleton
Journal: BMJ (1984)

For patients in cardiogenic shock, several devices can serve as a “bridge,” ie, provide circulatory support and allow the patient to live long enough to recover or to receive a heart transplant or a long-term device. Options include an intraaortic balloon pump, TandemHeart, Impella, extracorporeal membrane oxygenation (ECMO), and CentriMag. Which device to use depends on individual patient needs, local expertise, and anatomic and physiologic considerations.
Collagen VI serves as potent growth stimulator for human myofibroblastic ITO-cells Dept. of Gastroenterology and Hepatology, *Dept. of Surgery, Klinikum Benjamin Franklin, Free University of Berlin
Journal: Hepatology (1995)

The activation of pancreatic stellate cells (PSCs) is thought to be a potential mechanism underlying islet fibrosis, which may contribute to progressive β-cell failure in type 2 diabetes. Recently, we demonstrated that antioxidants reduced islet fibrosis in an animal model of type 2 diabetes. However, there is no in vitro study demonstrating that high glucose itself can induce oxidative stress in PSCs. Thus, PSCs were isolated and cultured from Sprague Dawley rats, and treated with high glucose for 72 h. High glucose increased the production of reactive oxygen species. When treated with high glucose, freshly isolated PSCs exhibited myofibroblastic transformation. During early culture (passage 1), PSCs treated with high glucose contained an increased number of α-smooth muscle actin-positive cells. During late culture (passages 2–5), PSCs treated with high glucose exhibited increases in cell proliferation, the expression of fibronectin and connective tissue growth factor, release of interleukin-6, transforming growth factor-β and collagen, and cell migration. Finally, the treatment of PSCs with high glucose and antioxidants attenuated these changes. In conclusion, we demonstrated that high glucose increased oxidative stress in primary rat PSCs, thereby facilitating the activation of these cells, while antioxidant treatment attenuated high glucose-induced PSC activation.
THE "BUGABOO OF THE MAD DOG."
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Blood for sale.
Journal: BMJ (1968)

knowledge of variations in the molecular struc- ture of genes and proteins and their effects in man (p.135).Pacing in Heart Block: Though specific treat- ment of conduction defects complicating myo- cardial infarction is not always successful or necessary, the selection of the minority that will benefit cannot be made in advance.All patients with second degree atrioventricular block or more serious defects should have transvenous electrodes inserted (p.142).Aphthous Ulceration: Steroid treatment does not appear to alter incidence or duration, and the risks of its use are not justified by the results (p.147).Leader at p. 131.Training and Breathing: Graduated programme of physical exercise improved tolerance in nine out of ten patients with obstructive airways disease (p.150).Renal Artery Reconstruction: Two cases of acute reversible contralateral renal failure after surgery (p.152).Cortisol Levels and Lung Cancer: While plasma cortisol levels were raised in cancer patients, 0
Renal-transplant ureteral obstruction simulating retroperitoneal fibrosis
Authors: R. J. Krane
Journal: JAMA (1973)

Two kidney transplant recipients developed impairment of renal function that was subsequently found to be due to retroperitoneal fibrosis. In one patient, the precipitating event was trauma with retroperitoneal hemorrhage, whereas in the other, it was talc retroperitonitis. Since the host ureter was uninvolved by the fibrotic process, return to normal renal function was achieved in both cases by donor-host pyeloureterostomy. Retroperitoneal fibrosis should be considered in any kidney transplant patient with failing renal function; the fibrosis surrounding the transplanted ureter can lead to obstructive uropathy in spite of a normal ureteral caliber, and thus may be confused with other causes of failing kidney function.
Isthmian Sanitation
Authors: J. E. Walker
Journal: JAMA (1905)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Vitrectomy
Authors: Donald M. Shafer
Journal: New England Journal of Medicine (1976)

The surgical removal of the vitreous from the eye has become the most dramatic development in ophthalmic surgery in years. The deep posterior vitrectomy is used in traumatic vitreous hemorrhages, intraocular perforations and foreign bodies, complicated retinal detachments and especially in diabetic vitreous hemorrhages. Most of these conditions, until the past few years, resulted in hopelessly blind eyes. A less extensive removal of the anterior vitreous only has salvaged many eyes in the last three years during routine cataract extraction. The sensational acceptance of vitrectomy of all types is shown by the 1600 per cent increase in vitrectomies for 1975 . . .
Cost-Effectiveness of Interferon-α as Maintenance Therapy in Chronic Myelogenous Leukemia
Authors: Michael W. Kattan
Journal: Annals of Internal Medicine (1997)

Letters15 April 1997Cost-Effectiveness of Interferon-α as Maintenance Therapy in Chronic Myelogenous LeukemiaMichael W. Kattan, PhD and J. Robert Beck, MDMichael W. Kattan, PhDBaylor College of Medicine, Houston, TX 77030Search for more papers by this author and J. Robert Beck, MDBaylor College of Medicine, Houston, TX 77030Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-126-8-199704150-00027 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Because the estimated yearly costs per patient have been shown to differ [1], we do not dispute the assertions of Messori and colleagues that interferon-α treatment may be somewhat more expensive in Germany and Italy than the $1500 figure used as our baseline monthly cost. This uncertainty in cost motivated the sensitivity analysis in our Figure 4. We also agree that $50 000 per QALY seems to be the de facto cutoff for reimbursable therapy.It seems that the primary reason for this difference in cost of treatment is that our analysis is based on the amount of ...References1. Schofield JR, Robinson WA, Murphy JR, Rovira DK. Low doses of interferon-α are as effective as higher doses in inducing remissions and prolonging survival in chronic myeloid leukemia. Ann Intern Med. 1994; 121:736-44. Google Scholar2. Ozer H, George SL, Schiffer CA, Rao K, Rao PN, Wurster-Hill DH, et al. Prolonged subcutaneous administration of recombinant α 2b interferon in patients with previously untreated Philadelphia chromosomepositive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival. Cancer and Leukemia Group B study 8583. Blood. 1993; 82:2975-84. Google Scholar Author, Article, and Disclosure InformationAffiliations: Baylor College of Medicine, Houston, TX 77030 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 April 1997Volume 126, Issue 8Page: 664-665KeywordsBody surface areaChronic myelogenous leukemiaDecision analysisDrugsQuality adjusted life years Issue Published: 15 April 1997 CopyrightCopyright © 1997 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...